Galderma Pharma S.A. and Spirig Pharma A.G. entered into a definitive agreement under which Galderma will acquire Spirig. Spirig's products treat conditions such as solar damage, skin barrier function impairment, and actinic keratosis. Leading brands include Excipial, Daylong, and Daylong Actinica. Galderma intends to utilize Spirig's Egerkingen location as headquarters to its Swiss market operations. The global corporate headquarters of Galderma remain in Lausanne. The transaction is expected to close in early 2013, subject to the fulfillment of customary closing conditions.